Article

Let's Chat About GI Cancers

Author(s):

Join us on Tuesday, April 10 at 1 p.m. EST for our monthly #CureConnect tweet chat, where we’ll focus on our recent gastrointestinal cancers special issue.

The world of gastrointestinal (GI) cancers is rapidly changing, and we would love to hear from our readers about it — whether you are 10 years with no evidence of disease or just starting out treatment.

Join us on Tuesday, April 10 at 1 p.m. EST for our monthly #CureConnect tweet chat, where we’ll focus on our recent gastrointestinal cancers special issue.

We will discuss the boom of immunotherapy in the field, which is providing great outcomes for patients whose tumors are classified as microsatellite instability-high (MSI-H). But with immunotherapy treatment comes a new class of side effects and things to look out for during treatment.

But immunotherapy is not the only major advance that we’ll talk about. Chemotherapy and new surgery techniques are still providing benefit for many GI cancer types, as presented in the 2018 Gastrointestinal Cancers Symposium.

Finally, we’ll discuss selfless acts and amazing feats that help to continue to move the field of GI cancers forward. We will reflect on the generosity of the late Cindy Stowell who won more than $100,000 on Jeopardy! However, shortly after appearing on the game show, Stowell passed away from colorectal cancer, and left her earnings to fund immunotherapy research.

We’d love to hear about your experiences with GI cancers — be it as a patient, survivor or caregiver. See you on Tuesday!

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Image of doctor with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Related Content